Enter your login e-mail to the account
Search
Search parameters
Search results
- Současnost a perspektivy léčby dyslipidémií
doc. MUDr. Jan Bultas, CSc., MUDr. Debora Karetová
(1/2004, Main topic ) - Rosuvastatín: nový inhibítor 3-hydroxy-3-methylglutaryl koenzým a reduktázy
doc. MUDr. Martin Gajdoš,CSc., MUDr. Ľubica Cibulová, RNDr. Zora Krivošíková, PhD.,
(1/2004, Medicine ) - Chyby a úskalí terapie statiny
MUDr. Lubor Goláň
(1/2004, Main topic ) - Combined hypolipidemic therapy in current clinical practice
MUDr. Ľubomíra Fábryová, PhD.
(6/2014, Review articles ) - Comparison of efficacy and safety of atorvastatin in a dosage of 20 mg and 30 mg in general practitioners’ practice
MUDr. Martin Čaprnda, PhD., Mgr. Ján Farkašovský, PharmDr. Silvia Encingerová, Mgr. Oliver Tlčimuka
(5/2016, Original articles & case reports ) - Reach target LDL cholesterol more effective dose of atorvastatin 30 mg in the practice of general practitioners
MUDr. Martin Čaprnda, PhD., MUDr. Ján Hencel, MSc., Mgr. Ján Farkašovský, PharmDr. Silvia Encingerová, Mgr. Oliver Tlčimuka
(5/2015, Original articles & case reports ) - WHAT IS THE POSITION OF STATINS IN THE TREATMENT OF PATIENTS WITH HEART FAILURE?
prof. MUDr. Andrej Dukát, CSc., FESC, doc. MUDr. Ľudovít Gašpar, CSc.,, doc. MUDr. Jana Sirotiaková, CSc., MUDr. Peter Minárik
(9/2006, Main topic ) - Pharmacological therapy and non-pharmacological measures in patient after myocardial infarction
prof. MUDr. Peter Mitro, PhD.
(2/2011, Review articles ) - HYPOLIPIDEMIKÁ V REÁLNEJ PRAXI A V PERSPEKTÍVE
prof. MUDr. Milan Kriška, DrSc.
(10/2007, clearly ) - MANAGEMENT OF ATHEROGENIC DYSLIPIDAEMIA IN THE METABOLIC SYNDROME
MUDr. Ľubomíra Fábryová
(S4/2007, Supplement ) - STATINS – DO THEY HAVE DOMINANT POSITION IN CARDIOVASCULAR PREVENTION? LIPID LOWERING AND PLEIOTROPIC EFFECTS OF STATINS
doc. MUDr. Daniel Pella, PhD., MUDr. Viola Vargová, PhD., MUDr. Ján Fedačko, MUDr. Richard Raši
(1/2007, clearly ) - IMMUNOMODULATORY EFFECTS OF STATINS
doc. MUDr. František Gazdík, PhD.
(5/2007, clearly ) - MANAGING DYSLIPIDAEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE
MUDr. Ľubomíra Fábryová
(10/2005, Topic ) - Ezetimibe in the treatment of hypercholesterolaemia
doc. MUDr. David Karásek, Ph.D.
(3/2020, Review articles ) - Role of niacin in a hypolipidaemic treatment in high cardiovascular risk patients
prof. MUDr. Andrej Dukát, CSc., doc. MUDr. Ľudovít Gašpar, CSc., MUDr. Peter Minárik, doc. MUDr. Martin Wawruch, PhD., doc. MUDr. Stanislav Oravec, CSc., MUDr. Peter Sabaka
(1/2010, Topic of the year ) - Cardiovascular risk in diabetics
prof. MUDr. Miroslav Souček, CSc., MUDr. Petr Žák
(6/2015, Review articles ) - Combined hypolipidemic therapy using statins and fibrates reducing the cardiovascular risk in the patients with atherogenic dyslipidemia
prof. MUDr. Vladimír Bláha, CSc.
(4/2010, Topic of the year ) - New options in diagnostics and treatment of familial hypercholesterolemia
MUDr. Šárka Tesařová, Prof. MUDr. Michal Vrablík, Ph.D.
(3/2019, Review articles ) - XIV. medzinárodné sympózium o ateroskleróze v Ríme
MUDr. Ľubomíra Fábryová
(9/2006, Events ) - Safety treatment with statins
prof. MUDr. RNDr. Rudolf Pullmann, PhD.
(1/2014, Review articles ) - CONGESTIVE HEART FAILURE TREATMENT
prof. MUDr. Viliam Bada, CSc.
(11/2007, Topic ) - Statins and ezetimibe – current position in the treatment of dyslipidaemias (cardiovascular prevention)
doc. MUDr. Jana Sirotiaková, PhD., RNDr. Miriam Zagyiová
(10/2009, Topic of the year ) - Srdcové zlyhávanie 2016 (HFA/ESC) a 3. svetový kongres o akútnom srdcovom zlyhaní, Florencia, Taliansko, 21. – 24. mája 2016, 1. časť
doc. MUDr. Marian Sninčák, PhD., mim. prof.
(4/2016, Events )
- The antidepressants treatment in patients with high cardiovascular risk: benefit or risk?
MUDr. Radkin Honzák, Milan Vrána
(6/2009, Review articles )
- Statins and myopathy
prof. MUDr. Zdeněk Ambler, DrSc. †
(6/2013, Review articles ) - Toxic myopathies
doc. MUDr. Edvard Ehler, CSc. , Prof. MUDr. Josef Zámečník, Ph.D.
(6/2016, Review articles ) - Statins and neuroprotective effects
prof. MUDr. Ivana Štětkářová, CSc., MHA, FEAN, PharmDr. Aleš Dvořák, MBA
(1/2021, Review articles ) - Statin myopathy
Prof. MUDr. Josef Bednařík, CSc., MUDr. Eva Vlčková, Ph.D., MUDr. Tomáš Horák
(1/2017, Main topic )
- Recommendations for diagnosis and treatment of dyslipidaemia in children and adolescents
MUDr. Ľubomíra Fábryová, PhD., MUDr. Anna Hlavatá, PhD.
(S1/2011, Review articles )
- HYPOLIPIDEMIKÁ V REÁLNEJ PRAXI A V PERSPEKTÍVE
prof. MUDr. Milan Kriška, DrSc., MUDr. Ján Kriška
(1/2008, Drug classes ) - STATÍNY – MAJÚ DOMINANTNÉ MIESTO V KARDIOVASKULÁRNEJ PREVENCII? LIPIDY ZNIŽUJÚCE A PLEIOTROPNÉ ÚČINKY STATÍNOV
doc. MUDr. Daniel Pella, PhD.
(2/2007, clearly )
- Novel targeted therapeutics in dyslipoproteinemia
PharmDr. Ľubica Lehocká, PhD., PharmDr. Lucia Masaryková, PhD., PharmDr. Anna Oleárová, PhD., MPH, MUDr. Katarína Jurečková
(3-4/2015, Current pharmacotherapy ) - What can statins do in the management of cardiovascular deseases?
MUDr. Marta Filková, prof. MUDr. Ján Murín, CSc.,, MUDr. Miroslav Pernický
(1/2013, Current pharmacotherapy ) - Dyslipidémie ako rizikový faktor kardiovaskulárnych ochorení: dôraz na familiárnu hypercholesterolémiu, jej včasnú diagnostiku a terapiu
Doc. PharmDr. Adriana Duriš Adameová, PhD.
(2/2018, Current pharmacotherapy ) - Current Possibilities of Dyslipidema Therapy
doc. RNDr. Magdaléna Fulmeková, CSc., PharmDr. Lucia Masaryková, PharmDr. Ľubica Lehocká, PhD.
(2/2011, Current pharmacotherapy ) - Safety treatment with statins
prof. MUDr. RNDr. Rudolf Pullmann, PhD.
(4/2013, Clinical pharmacy ) - Generics and their therapeutic position, the risk of substitution in pharmacies
MUDr. Karolína Hronová
(1/2017, Current pharmacotherapy )
- Periférne artériové ochorenie dolných končatín a globálne kardiovaskulárne riziko – možnosti ovplyvnenia v klinickej praxi
MUDr. Denisa Čelovská, PhD., prof. MUDr. Viera Štvrtinová, CSc., MUC. Mária Balgová
(1/2018, Main topic ) - Abstrakty
(1/2009, Abstracts ) - Statins and ezetimibe – current position in the treatment of dyslipidaemias (cardiovascular prevention)
doc. MUDr. Jana Sirotiaková, PhD., RNDr. Miriam Zagyiová
(4/2010, Drugs & drug classes )